In today's Pharmaceutical Executive Daily, Jewel Jones argues that pharma's traditional metrics catch patient disengagement only after trust has already broken down, a pharma dealmaking roundup covers CSL's partnership with Alentis Therapeutics worth up to $1.56 billion for the claudin-1-targeting agent lixudebart and Jiangsu Nhwa Pharmaceutical's licensing deal for Somnivera's sleep-disorder asset, and Corxel's Bo Liang calls GLP-1 therapies reaching bariatric-surgery-level weight loss the most surprising development in obesity medicine in the past decade.
Jewel Jones argues that pharma typically measures patient disengagement through lagging indicators like adherence, initiation, and outcomes, by which point the underlying trust breakdown has already happened. Jones contends that earlier warning signs — an urgent question left unasked in the exam room, a follow-up appointment that never gets scheduled, educational content that goes ignored — surface well before they show up in the metrics pharma typically tracks, and that companies willing to monitor those signals can intervene before disengagement becomes measurable.
Two licensing deals headline today's dealmaking roundup, each extending an established player's pipeline through an external asset. CSL has entered a global partnership with Alentis Therapeutics worth up to $1.56 billion, paying $355 million upfront to co-develop lixudebart, a first-in-class claudin-1-targeting agent, through a Phase III trial in AAV-RPGN and Phase II studies in FSGS and PSC, with CSL taking 55% of profits to Alentis's 45%. Separately, Jiangsu Nhwa Pharmaceutical licenses a clinical-stage sleep-disorder asset from Somnivera for $10.5 million upfront and up to $507 million in milestones, taking a 15% equity stake while retaining rights in Mainland China, Hong Kong, Macau, and Taiwan as Somnivera holds the rest of the world.
Finally, Corxel chief medical officer Bo Liang calls out the most surprising development in obesity medicine over the past decade: GLP-1 therapies now matching the weight-loss efficacy of bariatric surgery. Liang, who spent 11 years at Novo Nordisk leading global clinical development for semaglutide, says some compounds now deliver more than 10-15% body weight reduction, calling the leap from early treatments like Saxenda to today's results the single most significant advancement he has seen in the field.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
